For example, studies have shown that plasma-derived sEVs carry mutant DNA (e.g., EGFR T790M, KRAS G12D and TP53 R273H) serving as potential biomarkers of colon, lung, and pancreatic cancers [29–31]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.